Indaptus Therapeutics Inc. Common Stock INDP · Stock Open Indaptus Therapeutics Inc. Common Stock in new tab
Indaptus Therapeutics Inc. Common Stock Analysis (INDP)
Is Indaptus Therapeutics Inc. Common Stock a good investment? Indaptus Therapeutics Inc. Common Stock (INDP) is currently trading at 3.09 USD.
Earnings Schedule: Indaptus Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 17, 2026. The market consensus estimate for Forward EPS is -1.39.
Investor FAQ
Does Indaptus Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Indaptus Therapeutics Inc. Common Stock?
Indaptus Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 17, 2026. The company currently has a trailing EPS of -3.56.
Company Profile
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 30, 2020 | 1:20 |
| July 27, 2021 | 1:4 |
| June 27, 2025 | 1:25 |
Community Discussion